| ²é¿´: 1250 | »Ø¸´: 0 | |||
Ä«Öñ¾Óʿгæ (³õÈëÎÄ̳)
|
[½»Á÷]
ʲôÊÇFDA½ô¼±Ê¹ÓÃÊÚȨ£¿¸½Ð¹ÚÒßÃçFDA¹Ù·½ÊÚȨ·¾¶£¡
|
|
01. ʲôÊǽô¼±Ê¹ÓÃÊÚȨ? ½ô¼±Ê¹ÓÃÊÚȨ£¨Emergency Use Authorization, EUA£©ÊÇÒ»ÖÖÃÀ¹ú·¨ÂÉ»úÖÆ£¬¿ÉÈÃFDAͨ¹ý´Ù½øÔÚÍ»·¢¹«¹²ÎÀÉúʼþÆÚ¼äËùÐèµÄÒ½ÁƲúÆ·µÄ¿ÉÓÃÐÔ£¬À´°ïÖúÔöÇ¿¹ú¼ÒÕë¶Ô»¯Ñ§¡¢ÉúÎï¡¢·ÅÉäÒÔ¼°ºËÍþвµÄ¹«¹²ÎÀÉú±£»¤¡£¸ù¾ÝÃÀ¹ú¡¶Áª°îʳƷ¡¢Ò©Æ·ºÍ»¯×±Æ··¨¡·£¨21 USC 360bbb-3£©µÄµÚ564Ìõ£¬FDA¿ÉÒÔÔÚ·ûºÏ·¨¶¨±ê×¼£¬ÇÒÓпÆÑ§Ö¤¾ÝÖ§³ÖʹÓõÄǰÌáÏ£¬Í¨¹ýEUAÔÊÐí£¨a£©Ê¹ÓÃδ¾Åú×¼µÄÒ½ÁƲúÆ·£¨ÀýÈ磬ҩƷ¡¢ÒßÃç»òÕï¶ÏÉ豸£©£¬»ò£¨b£©À©´óÒÑÅú×¼²úÆ·ÔÚÉÐδ»ñÅú×¼µÄÊÊÓ¦Ö¢»òÊÊÓ÷¶Î§µÄʹÓã¬ÔÚ½ô¼±Çé¿öÏÂÓÃÓÚÓÉ»¯Ñ§¡¢ÉúÎï¡¢·ÅÉäºÍºËÍþвÒýÆðµÄÑÏÖØ»òΣ¼°ÉúÃüµÄ¼²²¡»ò×´¿öµÄÕï¶Ï¡¢ÖÎÁÆ»òÔ¤·À¡£ 02. ½ô¼±Ê¹ÓÃÊÚȨµÄ±ê×¼ ¸ù¾ÝFDAÓÚ2017Äê1Ô°䲼µÄÖ¸µ¼ÔÔò, ¿ÉÒÔ¿¼ÂÇEUAµÄ²úÆ·°üÀ¨ÉÐδͨ¹ý¡¶Áª°îʳƷ¡¢Ò©Æ·ºÍ»¯×±Æ··¨¡·£¨505¡¢510£¨k£©ºÍ515²¿·Ö£©»ò¡¶¹«¹²ÎÀÉú·þÎñ·¨¡·£¨351²¿·Ö£©Åú×¼»òÐí¿ÉµÄ²úÆ·¡£EUA²úÆ·ÐèÒªÂú×ãÏÂÁÐËÄÌõ±ê×¼£º a.ÑÏÖØ»òÍþвÉúÃüµÄ¼²²¡»ò×´¿ö £¨Serious or Life-Threatening Disease or Condition£© b.ÓÐЧÐÔÖ¤¾Ý (Evidence of Effectiveness) ¿ÉÒÔ¿¼ÂÇEUAµÄÒ½ÁƲúÆ·ÊÇÖ¸¡°¿ÉÄÜÓÐЧ¡±Õï¶Ï¡¢ÖÎÁÆ»òÔ¤·ÀÓÉ»¯Ñ§¡¢ÉúÎï¡¢·ÅÉäºÍºËÍþвÒýÆðµÄÑÏÖØ»òΣ¼°ÉúÃüµÄ¼²²¡»ò×´¿ö¡£EUAµÄ¡°¿ÉÄÜÓÐЧ¡±±ê×¼ËùÌṩµÄÖ¤¾ÝˮƽµÍÓÚFDAÓÃÓÚ²úÆ·Åú×¼µÄ¡°ÓÐЧÐÔ¡±±ê×¼¡£FDA»áʹÓ÷çÏÕÊÕÒæ·ÖÎöÖð°¸ÆÀ¹À¿ÉÄÜEUA²úÆ·µÄDZÔÚЧÁ¦¡£Èç¹û»ùÓÚÏÖÓеÄÈ«²¿¿ÆÑ§Ö¤¾ÝºÏÀíµØÈÏΪ¸Ã²úÆ·¿ÉÄܶÔÌØ¶¨ÓÃ;ÓÐЧ£¬²¢ÇÒ·ûºÏEUAµÄÆäËû·¨¶¨±ê×¼£¬FDA¿ÉÒÔÊÚÓè¸Ã²úÆ·EUA¡£ c.·çÏÕÊÕÒæ·ÖÎö (Risk-Benefit Analysis) Èç¹ûFDA¾ÆÀ¹ÀÈ·¶¨¸Ã²úÆ·ÔÚÓÃÓÚÕï¶Ï¡¢Ô¤·À»òÖÎÁÆÒÑÈ·¶¨µÄ¼²²¡»ò×´¿öʱ£¬ ÆäÒÑÖªºÍDZÔÚµÄÒæ´¦´óÓڸòúÆ·ÒÑÖªºÍDZÔڵķçÏÕ£¬Ôò¿ÉÒÔ¿¼Âǽ«¸Ã²úÆ·ÓÃÓÚEUA¡£ ÔÚÈ·¶¨²úÆ·ÒÑÖªºÍDZÔÚµÄÒæ´¦ÊÇ·ñ³¬¹ýÆäÒÑÖªºÍDZÔڵķçÏÕʱ£¬FDA»á²é¿´ËùÓпÆÑ§Ö¤¾ÝÒÔ½øÐÐÕûÌå·çÏÕÊÕÒæÆÀ¹À¡£´ËÀàÖ¤¾Ý¿ÉÒÔÓжàÖÖÀ´Ô´£¬°üÀ¨£¨µ«²»ÏÞÓÚ£©£º¹úÄÚÍâÁÙ´²ÊÔÑéµÄ½á¹û¡¢¶¯ÎïÄ£Ð͵ÄÌåÄÚ¹¦Ð§Êý¾ÝÒÔ¼°ÌåÍâÊý¾Ý¡£¼øÓÚµ±Ç°µÄ¿ÆÑ§ÖªÊ¶Ë®Æ½£¬FDA»¹½«ÆÀ¹À¿ÉÓÃÖ¤¾ÝµÄÖÊÁ¿ºÍÊýÁ¿¡£ d.ûÓÐÌæ´úÆ· £¨No Alternatives£© FDA¿¼ÂÇEUA²úÆ·£¬µ±Ç°±ØÐëûÓÐ×ã¹»µÄÒÑÅú×¼ºÍ¿ÉÓõÄÌæ´úÆ·ÓÃÓÚÕï¶Ï¡¢Ô¤·À»òÖÎÁƼ²²¡»ò×´¿ö¡£Èç¹ûÒÑÅú×¼µÄÌæ´úÆ·µÄ¹©Ó¦²»×ãÒÔÍêÈ«Âú×ã½ô¼±ÐèÇóʱ£¬Ôò¿ÉÄܻὫDZÔÚµÄÌæ´ú²úÆ·ÊÓΪ¡°²»¿ÉÓᱡ£ 03. »ñµÃ½ô¼±Ê¹ÓÃÊÚȨµÄ³ÌÐò ½ô¼±Ê¹ÓÃÊÚȨµÄÉêÇëºÍFDAÉóÆÀÐÂÒ©ÉÏÊÐÉêÇ루NDA/BLA£©ÊDz»Í¬µÄ¡£½ô¼±Ê¹ÓÃÊÚȨÓÉÉú²úÉÌ»òÆäËû»ú¹¹¸ù¾ÝFDA¶ÔÏà¹ØÉêÇë×ÊÁϵÄÒªÇóÏòFDAÓйز¿ÃÅÌá³öÉêÇë¡£ FDAÔÚÊÕµ½ÉêÇëºó»á¸ù¾ÝÉêÇëµÄÄÚÈÝ¡¢²úÆ·ÌØµã¼°ÆäËûһЩÒòËØÈ·¶¨ÓÅÏÈÉóÆÀ³Ì¶È£¬×î¿ì¿ÉÄÜÔÚÊýСʱ»òÊýÌìÄÚ×ö³ö¾ö¶¨ÊÇ·ñͬÒâ½ô¼±Ê¹ÓÃÊÚȨ¡£ ½ô¼±Ê¹ÓÃÊÚȨÊÇ¿ÉÄܱ»³·ÏûµÄ¡£FDAÓÐÔðÈζ¨ÆÚÉó²é½ô¼±Ê¹ÓÃÊÚȨµÄÊÊÓÃÐÔ£¬°üÀ¨Éó²éÓë½ô¼±Ê¹ÓÃÊÚȨ²úÆ·Ïà¹ØµÄгöÏֵĿÆÑ§Êý¾Ý¡£ÀýÈ磬 FDAÔÚ2020Äê3ÔÂ28ÈÕÅú×¼ÁËÁ×ËáÂÈàºÍÁòËáôÇÂÈàµÄ¿Ú·þÖÆ¼ÁÓÃÓÚÖÎÁÆÐÂÐ͹Ú×´²¡¶¾·ÎÑ×£¨COVID-19£¬ 2019¹Ú×´²¡¶¾·ÎÑ×£©µÄ½ô¼±Ê¹ÓÃÊÚȨ¡£FDA¸ù¾Ý½ØÖÁ¸ÃÈÕ¿É»ñµÃµÄ¿ÆÑ§ÐÅÏ¢£¬ÈÏΪÁòËáôÇÂÈàºÍÁ×ËáÂÈàÔÚÓÃÓÚÖÎÁÆÐÂÐ͹Ú×´²¡¶¾·ÎÑ×·½Ãæ¡°¿ÉÄÜÓÐЧ¡±£¬²¢ÇÒÁòËáôÇÂÈàºÍÁ×ËáÂÈàµÄÒÑÖªºÍDZÔÚÒæ´¦³¬¹ýÁ˸ÃÓÃ;µÄÒÑÖªºÍDZÔÚ·çÏÕ¡£Ëæºó£¬FDA¸ù¾Ý¶ÔÁòËáôÇÂÈàºÍÁ×ËáÂÈàÓÃÓÚÖÎÁÆÐÂÐ͹Ú×´²¡¶¾·ÎÑ׵ĿÆÑ§Ö¤¾ÝµÄ³ÖÐøÉó²é£¬È·¶¨Æä²»ÔÙ·ûºÏ¡¶Ê³Æ·¡¢Ò©ÎïºÍ»¯×±Æ··¨¡·µÚ564(c)(2)½ÚÖиÅÊöµÄ½ô¼±Ê¹ÓÃÊÚȨ·¨¶¨±ê×¼¡£FDAÈ·¶¨£¬ÁòËáôÇÂÈàºÍÁ×ËáÂÈ಻̫¿ÉÄܶÔÅ·ÃËÅú×¼µÄÐÂÐ͹Ú×´²¡¶¾·ÎÑ×ÖÎÁÆÓÐЧ¡£´ËÍ⣬¼øÓÚÕâÁ½ÖÖÒ©ÎïÁÙ´²Ê¹ÓúóÕýÔÚ·¢ÉúµÄÑÏÖØÐÄÔ಻Á¼Ê¼þºÍÆäËûÑÏÖØ¸±×÷Óã¬ÁòËáôÇÂÈàºÍÁ×ËáÂÈàµÄÒÑÖªºÍDZÔÚÒæ´¦²»ÔÙ³¬¹ýÆäÊÚȨʹÓõÄÒÑÖªºÍDZÔÚ·çÏÕ¡£¸ù¾ÝÕâÒ»½áÂÛ£¬FDAÓÚ2020Äê6ÔÂ15ÈÕ³·ÏûÁËÁòËáôÇÂÈàºÍÁ×ËáÂÈàÓÃÓÚÖÎÁÆÐÂÐ͹Ú×´²¡¶¾·ÎÑ׵Ľô¼±Ê¹ÓÃÊÚȨ¡£ 04. ÐÂÐ͹Ú×´²¡¶¾·ÎÑ׵Ľô¼±Ê¹ÓÃÊÚȨ ×Ô´Ó2020Äê2ÔÂÒÔÀ´£¬ FDAÒѾ¶ÔÐí¶àÓÃÓÚÐÂÐ͹Ú×´²¡¶¾·ÎÑ×£¨COVID-19£¬ 2019¹Ú×´²¡¶¾·ÎÑ×£©µÄÌåÍâÕï¶Ï²úÆ·¡¢Ò½ÁÆÆ÷е¡¢¸öÈË·À»¤É豸ÒÔ¼°Ò©ÎïºÍÉúÎïÖÆÆ·ÊÚÓèÁ˽ô¼±Ê¹ÓÃÊÚȨ¡£ÌرðÊǽüÈÕÏȺ󷢲¼ÁËÓÃÓÚÔ¤·ÀµÄйÚÒßÃç½ô¼±Ê¹ÓÃÊÚȨ£º 1£©2020Äê12ÔÂ11ÈÕ£¬Pfizer-BioNTech µÄÒßÃç»ñFDA½ô¼±Ê¹ÓÃÊÚȨ£¬ÓÃÓÚÔ¤·À16Ëê¼°ÒÔÉÏÈËȺµÄ2019¹Ú×´²¡¶¾·ÎÑס£ 2£©2020Äê12ÔÂ18ÈÕ£¬Moderna µÄÒßÃ磨mRNA-1273£©»ñFDA½ô¼±Ê¹ÓÃÊÚȨ£¬ÓÃÓÚÔ¤·À18Ëê¼°ÒÔÉÏÈËȺµÄ2019¹Ú×´²¡¶¾·ÎÑס£ ÓйØÉÏÊöÁ½¸öÒßÃçµÄ½ô¼±Ê¹ÓÃÊÚȨµÄ³ÌÐò£¬ Çë²Î¿¼FDA°ä²¼µÄ¡¶2019¹Ú×´²¡¶¾·ÎÑ×ÒßÃç´ÓÑо¿µ½½ô¼±Ê¹ÓÃÊÚȨµÄ·¾¶¡· £¨µã»÷¿´Í¼£©¡£ |
» ²ÂÄãϲ»¶
Çë½Ìõ£°·ËõºÏ·´Ó¦
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸´óÁ¬Àí¹¤ÖÆÒ©¹¤³Ìר˶086002£¬±¾¿Æ211£¬×Ü·Ö342
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ258È˻ظ´
ÖÆÒ©¹¤³ÌרҵÕÐÊÕµ÷¼Á£¬ÒªÇó¹ý¹ú¼ÒÏß
ÒѾÓÐ0È˻ظ´
ÎåÒØ´óѧҩÎﻯѧÉúÎïѧÍŶÓ-ÀîÀ¼Çå¿ÎÌâ×éÕÐÊÕµ÷¼ÁѧÉú
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ0È˻ظ´
Çóµ°°×ÍÆ¼ö£¬ÓÃÓÚʵÑé½ÌѧÖе°°×Ò©ÎïµÄ±í´ï
ÒѾÓÐ2È˻ظ´
342Ò»Ö¾Ô¸´ó¹¤ÖÆÒ©×¨Ë¶£¬±¾¿Æ211£¬Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
AcsÔÓÖ¾JAFCͶ¸åÇóÖú
ÒѾÓÐ4È˻ظ´
¿ÉÄÜÉϲ»Á˰¶£¿ÓÐÌõ¼þµÄ¿ÉÒÔ¿¼ÂÇÆäËû³ö·
ÒѾÓÐ0È˻ظ´














»Ø¸´´ËÂ¥